JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

CareDx Inc

Ouvert

SecteurSoins de santé

14.85 1.57

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.5

Max

15.15

Chiffres clés

By Trading Economics

Revenu

1.8M

-8.6M

Ventes

2M

87M

P/E

Moyenne du Secteur

13.819

37.003

Marge bénéficiaire

-9.885

Employés

644

EBITDA

9.3M

-4M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+22.7% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

71M

772M

Ouverture précédente

13.28

Clôture précédente

14.85

Sentiment de l'Actualité

By Acuity

80%

20%

347 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

CareDx Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2025, 23:50 UTC

Actions en Tendance

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct. 2025, 23:25 UTC

Résultats

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct. 2025, 23:18 UTC

Résultats

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct. 2025, 22:20 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct. 2025, 22:13 UTC

Résultats

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct. 2025, 21:38 UTC

Résultats

Correction to Visa Sales Jump Article

28 oct. 2025, 21:17 UTC

Résultats

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct. 2025, 21:07 UTC

Résultats

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct. 2025, 21:02 UTC

Résultats

Mondelez Tempers Outlook as Costs Rise

28 oct. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct. 2025, 23:02 UTC

Résultats

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct. 2025, 23:01 UTC

Résultats

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct. 2025, 22:46 UTC

Résultats

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct. 2025, 22:45 UTC

Résultats

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct. 2025, 22:44 UTC

Résultats

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct. 2025, 22:43 UTC

Résultats

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct. 2025, 22:42 UTC

Résultats

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct. 2025, 22:40 UTC

Résultats

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct. 2025, 22:22 UTC

Résultats

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct. 2025, 22:20 UTC

Résultats

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct. 2025, 22:02 UTC

Résultats

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

28 oct. 2025, 21:42 UTC

Market Talk
Résultats

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct. 2025, 21:20 UTC

Résultats

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct. 2025, 21:19 UTC

Résultats

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct. 2025, 21:18 UTC

Résultats

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparaison

Variation de prix

CareDx Inc prévision

Objectif de Prix

By TipRanks

22.7% hausse

Prévisions sur 12 Mois

Moyen 18 USD  22.7%

Haut 22 USD

Bas 14 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

2

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

14.77 / 18.49Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

347 / 373Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat